EORTC’s presence at ESMO 2025
17 Oct 2025
This year’s ESMO Congress, running from 17 to 21 October in Berlin, will feature a particularly strong presence from EORTC. We will be presenting ten abstracts, two of which are mini oral presentations, alongside six poster displays and two e-posters. Additionally, we will participate in three sessions: a special session highlighting patient-reported outcomes, an educational session showcasing perspectives on treatment optimisation and a patient advocacy session discussing diversity and inclusion in clinical trials.
Further details can be found in the table below.
EORTC ABSTRACTS |
|
| DEVELOPMENT OF A PATIENT INVOLVEMENT FRAMEWORK FOR THE EORTC: INSIGHTS FROM A SURVEY WITH PATIENT PARTNERS AND ONCOLOGY PROFESSIONALS.
Iryna Shakhnenko, Belgium |
Sunday, 19 October 15:50 - 15:55
Type: Mini Oral session Room: Bochum Auditorium - Hall 6.1 Abstract number: 2287MO |
| DISCONTINUATION AND ATTRITION RATES IN PHASE II OR PHASE III FIRST-LINE RANDOMIZED CLINICAL TRIALS (RCTS) OF SOLID TUMORS Eva Blondeaux, Italy |
Monday, 20 October 10:45 - 10:50 Type: Mini Oral session Room: Bochum Auditorium - Hall 6.1 Abstract number: 2279MO |
| EORTC GUCG 2238 DE-ESCALATE: A PRAGMATIC TRIAL TO REVISIT INTERMITTENT ANDROGEN-DEPRIVATION THERAPY IN METASTATIC HORMONE-NAÏVE PROSTATE CANCER IN THE ERA OF NEW AR PATHWAY INHIBITORS.
Guillaume Grisay, Belgium |
Saturday, 18 October 12:00-12:45 Type: Poster session Abstract number: 2519TiP |
| EFFICACY OF [177LU]LU-PSMA-617 IN PATIENTS WITH METASTATIC CLEAR CELL RENAL CELL CARCINOMA: A MULTICENTRE SINGLE-ARM PHASE II TRIAL (RENALUT)
Emmanuel Seront, Belgium |
Saturday, 18 October 12:00-12:45 Type: Poster session Abstract number: 2625P |
| DEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE FOR INDIVIDUALS AT RISK FOR HEREDITARY CANCER – PHASE 1-3A OF THE EORTC QLQ-HCR30
Veronika Engele & Anne Oberguggenberger, Austria |
Sunday, 19 October 2025 12:00-12:45
Type: Poster session Abstract number: 2579P |
| OUTCOMES OF FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC ADULT FIBROSARCOMA: POOLED ANALYSIS OF CLINICAL TRIALS FROM THE EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER SOFT TISSUE AND BONE SARCOMA GROUP
Fernando Campos, Brazil |
Monday, 20 October 12:00-12:45 Type: Poster session Abstract number: 2739P |
| EORTC 2014-HNCG PROLONG: PEMBROLIZUMAB AND RADIOTHERAPY FOR OLIGOMETASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK, RANDOMIZED PHASE III TRIAL
Irene Braña, Spain |
Monday, 20 October 12:00-12:45 Type: Poster session Abstract number: 1443TiP |
| MOLECULAR LANDSCAPE OF TUMORS FROM LONG-TERM SURVIVORS WITH GLIOBLASTOMA: LESSONS FROM ETERNITY (EORTC 1419)
Michael Weller, Switzerland |
Monday, 20 October 12:00-12:45 Type: Poster session Abstract number: 667P |
| DEVELOPMENT OF AN EORTC STRATEGY TO MEASURE HEALTH-RELATED QUALITY OF LIFE IN CANCER PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS: PHASE 1 AND 2
Louis Fox, United Kingdom |
Type: E-Poster Abstract number: 3191eP |
| EORTC GUCG 2418 STARBUST: “STRATEGIES FOR TREATMENT ADAPTATION FOLLOWING RE-EVALUATION OF THE BLADDER AFTER USING PRIMARY NEOADJUVANT SYSTEMIC THERAPIES”:
AN EORTC PLATFORM TRIAL
Guillaume Grisay, Belgium |
Type: E-Poster Abstract number: 3134eTiP |
SESSIONS |
|
|
SETTING INTERNATIONAL STANDARDS IN ANALYSING PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE ENDPOINTS (SISAQOL-IMI): 4-YEAR OUTCOME Madeline Pe, Belgium |
SPECIAL SESSION Friday, 17 October 14:35 - 14:50 Flensburg Auditorium - Hall 23 |
|
PERSPECTIVES FOR TREATMENT OPTIMISATION: CONSIDERATIONS FROM A HCP AND TRIALIST Denis Lacombe, Belgium |
EDUCATIONAL SESSION Sunday, 19 October 09:00 - 09:15 Bochum Auditorium - Hall 6.1 |
|
DIVERSITY, EQUITY AND INCLUSION IN CLINICAL TRIALS Denis Lacombe, Belgium |
PATIENT ADVOCACY SESSION Sunday, 19 October 17:15-17:30 Bochum Auditorium - Hall 6.1 |
Related News
EORTC participation at ISPOR Europe 2025 conference
7 Nov 2025
EORTC Quality of Life Group participating at the ISOQOL 2025 Conference
22 Oct 2025
New results and forthcoming trials presented at ESMO 2025 underline EORTC’s commitment to patient-centred research
21 Oct 2025
EORTC celebrates the 100th anniversary of p-value on World Statistics Day
20 Oct 2025
EORTC Announces Final Overall Survival Results from the PEACE-3 Trial
19 Oct 2025
Results from EORTC trial define new standard of care for aggressive brain tumours
18 Oct 2025
EORTC’s presence at EANO 2025
16 Oct 2025
EORTC celebrates Pink October: shaping the future of breast cancer care
15 Oct 2025
EORTC shines a light on advancements in radioligand therapy
8 Oct 2025
Treatment optimisation: making cancer treatment accessible and sustainable in Europe
24 Sep 2025
